Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 5, 2006 Brian Lawler	Adolor: Positive Results, Negative Reaction The market seems confused by good results from Adolor's latest clinical trial. Investors willing to take a gamble on Adolor at this price may be in for huge rewards if the company and Glaxo can convince the FDA of Entereg's viability.
The Motley Fool January 20, 2004 David Nierengarten	Adolor's Knocked-Out Drug The biotech's stock is pummeled after mixed-up trial results.
The Motley Fool September 14, 2007 Brian Lawler	FDA Keeps Adolor Waiting Adolor and partner GlaxoSmithKline continue playing the FDA waiting game, as the agency has still not decided whether to allow clinical trials of Adolor's top drug to continue.
The Motley Fool August 29, 2007 Brian Lawler	Adolor Stays in the Ring Adolor takes another run at getting FDA approval for its lead drug. Shares of the biotech firm are up on news the FDA had accepted for review additional information about its ileus medication, Entereg.
The Motley Fool April 11, 2007 Brian Lawler	Adolor: Down and Out? The drug developer announces dour clinical trial results. Shares of Adolor crashed nearly 60% on the news.
The Motley Fool March 15, 2007 Brian Lawler	Adolor's New Plan Adolor updates investors on its plans for its lead drug program.
The Motley Fool November 28, 2008 Brian Orelli	Will Patients Reject This Injection? Wyeth and Progenics release good trial data, but will patients want their constipation drug?
The Motley Fool February 28, 2007 Brian Lawler	Time to Buy Shares of Adolor? Drug developer Adolor announces its fourth-quarter financial results as investors await pivotal clinical trial results.
The Motley Fool June 12, 2007 Brian Lawler	Adolor Is Still Swinging The drugmaker bumps into the FDA as it pushes to do more testing of Entereg.
The Motley Fool November 8, 2006 Brian Lawler	Stumbling Block for Adolor Another approvable letter from the FDA means investors may have to be patient.
The Motley Fool January 24, 2008 Brian Lawler	Adolor Advisory Panel Aftermath An FDA advisory panel votes favorably on Adolor's lead drug.
The Motley Fool September 13, 2007 Brian Orelli	Progenics Progresses Progenics and partner Wyeth announce plans to start three new clinical trials on their constipation-relieving drug. The patient treatment time for the trials is relatively short, so investors won't have to wait too long to see how the drug performs.
The Motley Fool January 14, 2004 W.D. Crotty	Adolor Pains Investors A punishing 32% one-day plunge reminds us that biotech is no picnic.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool March 13, 2008 Brian Orelli	Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note.
The Motley Fool April 29, 2008 Brian Orelli	Will These Drugs Get FDA Approval? Discovery Laboratories and Adolor are waiting FDA decisions on their drugs next month.
The Motley Fool December 21, 2004 Seth Jayson	Buy Drug Fears? When headlines get bad, both value hunters and rule breakers should start feeling good about buying stock.
The Motley Fool January 22, 2008 Brian Lawler	Adolor Under the FDA's Spotlight The FDA releases its documents on Adolor's lead drug, with surprising good news in advance of an advisory panel discussion. Investors, take note.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool April 8, 2005 Charly Travers	The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care?
The Motley Fool May 1, 2007 Mike Havrilla	Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool October 15, 2009 Brian Orelli	This Partnership Will Go No Further Wyeth and Progenics call it quits.
The Motley Fool April 25, 2008 Brian Orelli	Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation.
The Motley Fool March 30, 2005 David Nierengarten	Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives?
The Motley Fool November 30, 2007 Brian Lawler	FDA Throws Adolor a Bone Pharmaceutical company Adolor gets an advisory panel hearing on its lead drug. Investors, take note.
The Motley Fool March 9, 2007 Brian Lawler	Progenics Gets Backed Up Progenics Pharmaceutics and drugmaker giant Wyeth announced a delay in one of their methylnaltrexone programs. Investors, take note.
The Motley Fool February 12, 2008 Brian Lawler	A Pre-Emptive Strike on the FDA Adolor will likely be waiting an extra three months for a decision on its lead drug Entereg.
The Motley Fool July 10, 2007 Brian Lawler	Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into.
BusinessWeek March 7, 2005 John Carey	Side Effects Of The Drug Scares New fears give rise to a more honest look at the risks for a pill-popping nation.
The Motley Fool December 13, 2005 Rich Duprey	Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors.
The Motley Fool June 22, 2011 Brian Orelli	Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
The Motley Fool March 1, 2006 Rich Duprey	Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware.
The Motley Fool November 18, 2004 Lawrence Meyers	Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool June 4, 2007 Brian Lawler	Progenics Is on the Clock The biotech's marketing application for its lead compound gets accepted for review. Investors, take note.
The Motley Fool December 28, 2004 W.D. Crotty	Pfizer: For Value Eyes Only While clearly not for conservative investors, this pharmaceutical deserves the attention of those looking for a value play.
The Motley Fool February 10, 2005 Karl Thiel	The Worst Has Happened. Time to Sell? Biotech stocks can be volatile, but dumping them in response to bad news isn't always the smartest option: Axonyx... Icos Pharmaceuticals... etc.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool March 31, 2008 Brian Orelli	Collateral Damage From an FDA Warning BioMimetic gets hit hard by a warning about a J&J drug.
The Motley Fool December 17, 2004 W.D. Crotty	Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news.
The Motley Fool July 23, 2007 Brian Lawler	Progenics Gets Back In the Game Being the first approved to market an oral compound to treat one of the more painful side effects from opioid use will be a boon to whichever drugmaker can reach this goal. With the competitior Adolor looking more likely to be out of this race, Progenics is in the pole position once again.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
The Motley Fool April 10, 2008 Brian Lawler	Glaxo Angers the FDA GlaxoSmithKline announces that the FDA has sent it a warning letter regarding its failure to meet certain post-marketing requirements for Avandia.
The Motley Fool February 2, 2005 Brian Gorman	Pfizer's Troubling Trust Issue The company is in danger of losing the public's confidence.
American Family Physician December 1, 2005 Christine Hsieh	Treatment of Constipation in Older Adults Effectiveness of a variety of treatments for chronic constipation in the elderly.
American Family Physician February 1, 2006	Chronic Constipation in Your Child An informative patient hand-out: What is constipation?... How common is chronic constipation... Why does my child have constipation?... etc.